Racial differences in tumor stage and survival for colorectal cancer in an insured population

Department of Family Medicine and Community Health, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
Cancer (Impact Factor: 4.89). 02/2007; 109(3):612-20. DOI: 10.1002/cncr.22437
Source: PubMed


Despite declining death rates from colorectal cancer (CRC), racial disparities have continued to increase. In this study, the authors examined disparities in a racially diverse group of insured patients.
This study was conducted among patients who were diagnosed with CRC from 1993 to 1998, when they were enrolled in integrated healthcare systems. Patients were identified from tumor registries and were linked to information in administrative databases. The sample was restricted to non-Hispanic whites (n = 10,585), non-Hispanic blacks (n = 1479), Hispanics (n = 985), and Asians/Pacific Islanders (n = 909). Differences in tumor stage and survival were analyzed by using polytomous and Cox regression models, respectively.
In multivariable regression analyses, blacks were more likely than whites to have distant or unstaged tumors. In Cox models that were adjusted for nonmutable factors, blacks had a higher risk of death from CRC (hazard ratio [HR], 1.17; 95% confidence interval [95% CI], 1.06-1.30). Hispanics had a risk of death similar to whites (HR, 1.04; 95% CI, 0.92-1.18), whereas Asians/Pacific Islanders had a lower risk of death from CRC (HR, 0.89; 95% CI, 0.78-1.02). Adjustment for tumor stage decreased the HR to 1.11 for blacks, and the addition of receipt of surgical therapy to the model decreased the HR further to 1.06. The HR among Hispanics and Asians/Pacific Islanders was stable to adjustment for tumor stage and surgical therapy.
The relation between race and survival from CRC was complex and appeared to be related to differences in tumor stage and therapy received, even in insured populations. Targeted interventions to improve the use of effective screening and treatment among vulnerable populations may be needed to eliminate disparities in CRC.

Download full-text


Available from: Eli Korner, Apr 13, 2015
8 Reads
  • Source
    • "As evidenced in Table 1, 72.8% of the studies identified in our review relied to some degree on claims data. Of the 294 articles selected for review, 21.8% (n ¼ 64) were claimsonly studies [7–70], 5.1% (n ¼ 15) were registry-only [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85], 51% (n ¼ 150) used claims and registry data together without any other supplemental data set [6,24,151–298], and the remaining 22.1% (n ¼ 65) used other data sources, primarily chart-based systems or hospital discharge data sets, either alone or in combination with claims and/or registry data [86–150]. Chartbased systems included paper or electronic health records (EHRs) as well as electronic medical record (EMR) databases, programmatically generated subsets of EHRs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The ISPOR Oncology Special Interest Group formed a working group at the end of 2010 to develop standards for conducting oncology health services research using secondary data. The first mission of the group was to develop a checklist focused on issues specific to selection of a sample of oncology patients using a secondary data source. A systematic review of the published literature from 2006 to 2010 was conducted to characterize the use of secondary data sources in oncology and inform the leadership of the working group prior to the construction of the checklist. A draft checklist was subsequently presented to the ISPOR membership in 2011 with subsequent feedback from the larger Oncology Special Interest Group also incorporated into the final checklist. The checklist includes six elements: identification of the cancer to be studied, selection of an appropriate data source, evaluation of the applicability of published algorithms, development of custom algorithms (if needed), validation of the custom algorithm, and reporting and discussions of the ascertainment criteria. The checklist was intended to be applicable to various types of secondary data sources, including cancer registries, claims databases, electronic medical records, and others. This checklist makes two important contributions to oncology health services research. First, it can assist decision makers and reviewers in evaluating the quality of studies using secondary data. Second, it highlights methodological issues to be considered when researchers are constructing a study cohort from a secondary data source.
    Value in Health 06/2013; 16(4):655-669. DOI:10.1016/j.jval.2013.02.006 · 3.28 Impact Factor
  • Source
    • "One possible explanation is ethnic difference. Asian colon cancer patients tend to experience better survival than Western patients in the same stage [9,11,12,15]. Our data showed that the observed OS was better than that predicted by AOL, although there was no statistical difference. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Adjuvant Online (AOL) is web-accessible risk-assessment model that predicts the mortality and the benefits of adjuvant therapy ( AOL has never been validated for Asian colon cancer patients. Methods Using the Yonsei Tumor Registry database, patients who were treated within the Yonsei University Health System between 1990 and 2005 for T1-4, N0-2, and M0 colon cancer were included in the calculations for survival. Observed and predicted 5-year overall survival was compared for each patient. Results The median age of the study population of 1431 patients was 60 years (range, 15–87 years), and the median follow-up duration was 7.9 years (range, 0.06–19.8 years). The predicted 5-year overall survival rate (77.7%) and observed survival (79.5%) was not statistically different (95% Confidential interval, 76.3–81.5) in all patients. Predicted outcomes were within 95% confidential interval of observed survival in both stage II and III disease, including most demographic and pathologic subgroups. Moreover, AOL more accurately predicted OS for patients with stage II than stage III. Conclusions AOL tended to offer reliable prediction for 5-year overall survival and could be used as a decision making tool for adjuvant treatment in Korean colon cancer patients whose prognosis is similar to other Asian patients.
    BMC Cancer 10/2012; 12(1):471. DOI:10.1186/1471-2407-12-471 · 3.36 Impact Factor
  • Source
    • "The overall CRC incidence rate ratio for African American versus non-Hispanic white groups is 1.21 among men and 1.26 among women [14]. In addition, African Americans tend to be diagnosed with later stage CRC than whites [13,15,16] and at a younger age [17]. There is scant direct information about the reasons for these disparities [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Microsimulation models are an important tool for estimating the comparative effectiveness of interventions through prediction of individual-level disease outcomes for a hypothetical population. To estimate the effectiveness of interventions targeted toward high risk groups, the mechanism by which risk factors influence the natural history of disease must be specified. We propose a method for evaluating these risk factor assumptions as part of model-building. We used simulation studies to examine the impact of risk factor assumptions on the relative rate (RR) of colorectal cancer (CRC) incidence and mortality for a cohort with a risk factor compared to a cohort without the risk factor using an extension of the CRC-SPIN model for colorectal cancer. We also compared the impact of changing age at initiation of screening colonoscopy for different risk mechanisms. Across CRC-specific risk factor mechanisms, the RR of CRC incidence and mortality decreased (towards one) with increasing age. The rate of change in RRs across age groups depended on both the risk factor mechanism and the strength of the risk factor effect. Increased non-CRC mortality attenuated the effect of CRC-specific risk factors on the RR of CRC when both were present. For each risk factor mechanism, earlier initiation of screening resulted in more life years gained, though the magnitude of life years gained varied across risk mechanisms. Simulation studies can provide insight into both the effect of risk factor assumptions on model predictions and the type of data needed to calibrate risk factor models.
    BMC Medical Informatics and Decision Making 09/2011; 11:55. DOI:10.1186/1472-6947-11-55 · 1.83 Impact Factor
Show more